SKYE Reports $12.4M Q4 Rev, $0.08 EPS, Initiates 400/600mg CBeyond Expansion Study, FDA Type C Feedback Informs Phase 2b Combo Design, 22.3% Weight Loss at 52 Weeks
Skye Bioscience, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $0.76
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS